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Summary
Granuphilin is a crucial component of the docking machinery of insulin-containing vesicles to the plasma membrane. Here,
we show that the granuphilin promoter is a target of SREBP-1c, a transcription factor that controls fatty acid synthesis, and
MafA, a b cell differentiation factor. Potassium-stimulated insulin secretion (KSIS) was suppressed in islets with adenoviral-
mediated overexpression of granuphilin and enhanced in islets with knockdown of granuphilin (in which granuphilin had
been knocked down). SREBP-1c and granuphilin were activated in islets from b cell-specific SREBP-1c transgenic mice,
as well as in several diabetic mouse models and normal islets treated with palmitate, accompanied by a corresponding
reduction in insulin secretion. Knockdown- or knockout-mediated ablation of granuphilin or SREBP-1c restored KSIS in
these islets. Collectively, our data provide evidence that activation of the SREBP-1c/granuphilin pathway is a potential
mechanism for impaired insulin secretion in diabetes, contributing to b cell lipotoxicity.Introduction
Insulin secretion by pancreatic b cells involves sequential intra-
cellular events. Initially, glucose oxidation results in ATP produc-
tion as controlled by intracellular energy-sensing mechanisms
(Bratanova-Tochkova et al., 2002). This is followed by closure
of ATP-dependent K+ channels leading to a change in mem-
brane voltage (depolarization), Ca2+ influx through voltage-de-
pendent Ca2+ channels, and vesicular transport of insulin-con-
taining granules, culminating in their exocytosis and release of
insulin (Rizzoli and Betz, 2005; Rorsman and Renstrom, 2003).
Theoretically, impaired insulin secretion could be caused by dis-
turbances in any stage of this highly regulated process (Weir and
Bonner-Weir, 2004). Current literature supports the concept that
disturbances of energymetabolism in b cells leading to impaired
ATP production are the primary pathological cause of impaired
insulin secretion following peripheral insulin resistance in type 2
diabetes mellitus (Kahn, 2003). This pathophysiologic process
can be observed in isolated islets from diabetic animal models
and is characterized by impairment of glucose-stimulated insu-
lin secretion (GSIS) (Diani et al., 2004). Meanwhile, potential per-
turbations in insulin secretion at steps following ATP production
in islets from the diabetic models as estimated by K+-stimulated
insulin secretion (KSIS) have not been fully investigated.
Studies to unveil the molecular basis for exocytosis of secre-
tory granules have been focused on the interactions between
components of the fusion machinery (Burgoyne and Morgan,CELL METABOLISM 4, 143–154, AUGUST 2006 ª2006 ELSEVIER INC.2003; Rizzoli and Betz, 2005; Rorsman and Renstrom, 2003),
including soluble N-ethylmaleimide-sensitive factor attachment
protein receptors (SNAREs: Vamp2/synaptobrevin, Syntaxin-
1a, and SNAP25) and SNARE-associated proteins (Munc13-1
and Munc18-1) on the plasma membrane, and small Rab
GTPase family members, Rab3 and Rab27a, on the vesicles.
Granuphilin is a Rab27a effecter specific to pancreatic b cells
and the pituitary gland. It has two isoforms, granuphilin-a and
-b, which derive from alterative splicing (Coppola et al., 2002;
Wang et al., 1999). Granuphilin directly binds to Rab27a, and
also to syntaxin-1a andMunc18-1, assisting in the docking of in-
sulin granules to the plasma membrane (Coppola et al., 2002;
Torii et al., 2002, 2004; Yi et al., 2002). Contrary to expectations,
overexpression of granuphilin in a b cell line inhibited insulin
secretion (Coppola et al., 2002; Torii et al., 2002). In addition,
granuphilin-null islets exhibited inhibition of vesicle docking,
yet insulin secretion was increased (Gomi et al., 2005). These
gain- and loss-of-function experiments implicated granuphilin
as playing a regulatory role in the exocytosis of insulin granules.
To date, the regulation of these vesicle proteins and the potential
role of granuphilin in b cell lipotoxicity and diabetes are largely
unknown.
SREBP-1c is a transcription factor established as a regulator
for biosynthesis of fatty acids and triglycerides (Shimano et al.,
1997a, 1997b). In addition to nutritional regulation of lipogenic
enzymes (Horton et al., 1998; Hasty et al., 2000; Matsuzaka
et al., 2004), SREBP-1c is found to play a role in insulin signalingDOI 10.1016/j.cmet.2006.06.009 143
A R T I C L Eby inhibiting IRS-2, the major insulin-signaling mediator in the
liver and in b cells (Ide et al., 2004; Takahashi et al., 2005). As
a model for lipotoxicity by endogenous fatty acids in pancreatic
b cells, we previously developed transgenic mice overexpress-
ing the active form of SREBP-1c under the insulin promoter.
These mice exhibited impaired insulin secretion in vivo due to
ATP depletion caused by enhanced lipogenesis and direct
UCP2 induction. In addition, these mice demonstrated loss of
b cell mass, presumably due to suppression of IRS-2 and PDX-
1 in islets from the transgenic mice (Takahashi et al., 2005). In
addition to inhibition of GSIS, SREBP-1c-overexpressing islets
exhibited decreased KSIS, which could indicate dysfunction in
insulin secretion at a phase following ATP production. Our cur-
rent study demonstrates that granuphilin is an SREBP-1c target
exhibiting a molecular link between b cell lipotoxicity and im-
paired insulin secretion in the pathogenesis of diabetes develop-
ment. These data provide a rational to study granuphilin as a
potential therapeutic target for treatment of diabetes.
Results
Granuphilin is activated by SREBP-1c in islets
We have previously demonstrated that insulin secretion is
blunted in islets isolated from nuclear SREBP-1c transgenic
mice under the control of rat insulin promoter I, whereas
SREBP-1-null islets demonstrated enhanced insulin secretion
compared to wild-type controls (Takahashi et al., 2005). Expres-
sion of the transgenewas barely detectable in the hypothalamus
and was essentially b cell-specific in this transgenic line (Fig-
ure S1A in the Supplemental Data available with this article
online). In the current study, we found that the negative effect
of SREBP-1c on insulin secretion encompassed not only GSIS
but also KSIS and induction by arginine (Figure 1A), suggesting
that insulin secretion defects caused by SREBP-1c occurred
post-ATP production. In an attempt to determine the molecular
mechanisms responsible, we explored the expression of genes
involved in vesicular transport of insulin granules in islets from
these mice. Among many different vesicle factors involved in
exocytosis of insulin granules, granuphilin was singly upregu-
lated by overexpression of SREBP-1c and suppressed in the
absence of SREBP-1c, as evidenced by real-time PCR (Fig-
ure 1B). Immunoblot analysis of islet proteins demonstrated
that wild-type islets mainly express granuphilin-a (Figure 1C),
and the ratio of granuphilin-a/-b mRNA was roughly 8 (data not
shown). Consistent with changes at the mRNA level, both gran-
uphilin-a and -b proteins were robustly induced by overexpres-
sion of SREBP-1c and reduced in SREBP-1c-null islets (Fig-
ure 1C). SREBP-1c slightly reduced Syntaxin-1a and Munc18-1
proteins but did not affect other related vesicle proteins such
as Rab27a, Rab3, Vamp2, and SNAP25 (Figure 1C). Induction
of granuphilin mRNA and proteins by acute overexpression of
adenoviral SREBP-1c was also observed in a murine insulinoma
cell line Min6 (Figure 1D) and islets (Figure 1E), respectively.
Granuphilin promoter is an SREBP target
We next sought to determine whether the granuphilin promoter
is a potential direct target of SREBP. Analysis of the GeneBank
database revealed that the promoter region of the murine gran-
uphilin gene contains two potential binding sites for SREBP
(SREs) and a single site for MafA, which was recently estab-
lished as an important factor for b cell-differentiation and func-144tion (MARE) (Hagman et al., 2005; Kajihara et al., 2003) (Fig-
ure S2). Activation of the granuphilin promoter by transcription
factors such as SREBPs, MafA, and others was tested in Min6
cells using a luciferase reporter gene fused to the 1.2 kb pro-
moter region ofmouse granuphilin (Granu-1200-Luc) (Figure 1F).
SREBP-1a and -1c robustly and SREBP-2 moderately stimu-
lated granuphilin promoter activity. MafA was found to be the
strongest activator of the granuphilin promoter. A similar pattern
of transactivation by these factors was also observed in non-
b cells (HEK 293 cells), suggesting that SREBP activation does
not require other b cell-specific factors (data not shown). Human
granuphilin promoter (0.5 kb) luciferase reporter was also acti-
vated by SREBPs and MafA (data not shown).
This region of themouse granuphilin promoter (Figure 2A) was
further analyzed as an SREBP target. Activation of the granuphi-
lin promoterwascompletely attenuatedwhenSREBPsweremu-
tated (YR mutants) to abolish their binding abilities to authentic
SREs (Figure 2B). Deletion studies suggested that the proximal
SRE is responsible for SREBP activation of granuphilin promoter
(Figure 2C). EMSA assays demonstrated direct and specific
binding of SREBPs to this SRE-1 (hereafter referred to as Gran-
uphilin SRE) and not SRE-2 (Figure 2E). Mutation of Granuphilin
SRE (Figure 2A) completely abolished the SREBP activation of
Granuphilin-Luc (Figure 2D). To determine the physiological
relevance of SREBP regulation of granuphilin, MIN6 cells were
treated with delipidated serum (DLS) and 25-hydroxycholesterol
(25-OH) to activate and suppress endogenous SREBPs, respec-
tively, via modulation of the sterol-regulated SERBP cleavage
system. The cells were also treated with T0901317, an LXR ago-
nist, to induce endogenous SREBP-1c. Granu-1200-Luc activity
was consistently up- and downregulated by these manipula-
tions, respectively, demonstrating that endogenous SREBPs
can also regulate granuphilin promoter activity (Figures 2F and
2G). Chromatin immunoprecipitation assays using MIN6 cells
confirmed direct binding of SREBP-1c to Granuphilin SRE
in vivo. The signal was increased by incubation with DLS and
T0901317 (Figure 2H). Collectively, these data demonstrate
that the granuphilin promoter is an SREBP target and that
SREBPs regulate granuphilin expression.
Granuphilin promoter is a MafA target
Next, we focused theMAREdownstreamof theGranuphilin SRE
in the granuphilin promoter as diagramed in Figure 3A. Activa-
tion of the granuphilin promoter by MafA was completely abol-
ished by deletion of the acidic domain of MafA (Figure 3B). De-
letion or mutation of the MARE dramatically suppressed the
promoter activity (Figures 3C and 3D). Direct, specific, and in
vivo binding of MafA to this MARE was confirmed by EMSA
and ChIP assay (Figures 3E and 3F). Considering the two neigh-
boring sites, potential synergism between SREBP-1c and MafA
was estimated. Both factors exhibited dose-dependent activa-
tion of granuphilin promoter, although MafA has a curve slightly
steeper and more saturable than SREBP-1c. Cotransfection of
both SREBP-1c and MafA caused only additive activation of
the granuphilin promoter (Figures 3G and 3H). In immunoprecip-
itation experiments, no significant protein-protein interactions
between SREBP-1c and MafA were detected (data not shown).
Granuphilin negatively regulates insulin secretion
To determine whether granuphilin could be directly involved
in insulin secretion, its expression was manipulated in isletsCELL METABOLISM : AUGUST 2006
SREBP-1c/granuphilin pathway in insulin secretionFigure 1. Influence of SREBP-1c on granuphilin
expression
Granuphilin and other fusion machinery proteins and
insulin secretion were estimated in islets from wild-
type (WT-Control), b cell-specific nuclear SREBP-1c
transgenic (TgRIP-SREBP-1c), and SREBP-1-null
mice (SREBP-1-KO) mice.
A)Basal (low glucose LG; 2.8mM), high glucose (HG;
20 mM), KCl- (30 mM), arginine- (3 mM), forskolin-
(10 mM), or TPA (0.5 mM)-stimulated insulin secretion
in isolated islets from age-matched (14- to 17-week-
old) male WT-Control (white bars), TgRIP-SREBP-1c
(black bars), and SREBP-1-KO (gray bars) mice.
Results were normalized to cellular DNA content.
*p < 0.01 and **p < 0.05 (versus WT-Control).
B)mRNA levels of the fusion machinery for exocyto-
sis of insulin granules in the indicated islets as quan-
tified by real-time PCR. Values were normalized to
the cyclophilin expression level. *p < 0.01 (versus
WT-Control).
C) Immunoblot analysis on total proteins (50 mg/lane)
of the fusionmachinery for exocytosis of insulin gran-
ules in the islets from indicated mice.
D) Northern blot analysis of granuphilin and
hSREBP-1 gene expression in mouse insulinoma
cell line, Min6. Cells were infected by adenoviral-
GFP or -SREBP-1c (500 MOI) for 48 hr. Total RNA
(15 mg/lane) was isolated and subjected to blot hy-
bridization with the indicated 32P-labeled probe.
E) Immunoblot analysis on nuclear or total proteins of
SREBP-1 and mouse granuphilin in the islets from
C57BL/6 mice with a-tubulin as a loading control. Is-
lets were infected with adenoviral-GFP or -SREBP-
1c (500 MOI) for 48 hr.
F) Activation of the granuphilin promoter by SREBPs
and MafA. The mouse granuphilin promoter region
(1.2 kb) was fused to a luciferase reporter gene
(Granu-1200-Luc). Min6 cells were cotransfected
with Granu-1200-Luc as a reporter gene, pSV-40-
Renilla as a reference, and the indicated expression
plasmids or an empty vector. The luciferase activity
was normalized to Renilla luciferase activity and as-
says were performed in triplicate. *p < 0.01 (versus
pcDNA3.1 group).
Results are expressed by mean 6 SEM. Studies
were performed in triplicate with sets of islets pooled
from 3–4 mice per replicate (A–C and E).isolated from C57BL/6 mice using adenoviral overexpression
and RNA interference (Figures S3A and S3B). Adenoviral over-
expression of granuphilin-a suppressed GSIS substantially
and KSIS completely but not basal secretion at low glucose con-
centration, consistent with previous report in a b cell line (Cop-
pola et al., 2002; Torii et al., 2002) (Figure S3C). Adenoviral
RNAi (RNAi-784) completely inhibited expression of both granu-
philin-a and-b. This knockdown of granuphilin resulted in a trend
toward increased GSIS, and significantly increased KSIS, which
is also consistent with a recent report describing granuphilin-null
mice (Gomi et al., 2005) (Figure S3C). Granuphilin-a overexpres-
sion and knockdown did not significantly change either insulin
content or ATP/ADP ratio in infected islets, demonstrating that
the modulation of insulin secretion by granuphilin occurred in
the process post-ATP production (Figures S3D and S3E).CELL METABOLISM : AUGUST 2006Granuphilin mediates SREBP-1 inhibition of KSIS
We also evaluated the effect of granuphilin knockdown by RNA
interference in SREBP-1c-overexpressing islets (Figures 4 and
S4). Granuphilin mRNA and protein levels were upregulated by
SREBP-1c in these islets in the basal state; however, expression
was completely abolished by granuphilin RNAi (Figures 4A and
4B). This suppression of granuphilin did not affect the protein
level of endogenous membrane SREBP-1c, transgenic nuclear
SREBP-1c, or MafA (Figure 4B). Other vesicle and related mol-
ecules were also unchanged at the protein and mRNA levels
(Figures 4C and S4A). However, the granuphilin knockdown
substantially ameliorated the decreased GSIS caused by
SREBP-1c overexpression and completely restored the sup-
pressed KSIS without changes in decreased ATP/ADP ratio
and increased triglyceride content (Figures 4D–4F). These data145
A R T I C L EFigure 2. Mouse granuphilin promoter analysis as
an SREBP target
A) Schematic representation of the mouse granuphi-
lin promoter with the sequence and location of po-
tential SREBP binding sites (SRE-1 and SRE-2).
The SRE-2 element has an inverted consensus se-
quence and partially overlaps with an E-box.
B) Transcriptional activities of nuclear SREBP-1a,
-1c, and -2 and their respective Tyr-Arg mutants on
Granu-1200-Luc in Min6 cells.
C) Effects of deletion of SREBP-1c activation in the
granuphilin promoter. Sequentially deleted luciferase
constructs of the granuphilin promoter, as indicated,
were used for transfection studies in Min6 cells.
D) Effects of a mutation in SRE-1 on SREBP activa-
tion of granuphilin promoter. Native (Granu-500-
Luc) or mutant-SRE-1 (mSRE-Luc) reporter gene
plasmids were cotransfected into Min6 cells with
pSV40-Renilla and expression plasmids for SREBPs.
E) EMSA with radio-labeled probes for the authentic
human LDL receptor SRE and granuphilin SRE-1 and
SRE-2. In vitro translated SREBP-1a, -1c, and -2
proteins were incubated with these labeled probes.
Specific binding was confirmed by super-shift using
their respective antibody.
F) Effect of endogenous SREBPs in Min6 cells on
Granu-1200-Luc. Cells were incubated with DMEM
in 7.5% FCS, in 7.5% DLS, an LXR agonist:
T0901317 (1 mM), and 25-hydroxycholesterol (25-
OH, 0.1 mg/ml).
G) Immunoblot analysis of endogenous SREBP-1
and granuphilin proteins in Min6 cells. Cells were in-
cubated with DMEM in 7.5% FCS, in 7.5% DLS, and
T0901317 (1 mM) for 48 hr.
H) In vivo binding of SREBP-1 to Granuphilin-SRE.
Chromatin prepared from the Min6 cells were sub-
jected to the ChIP assay with anti-mouse SREBP-1
antibody and rabbit IgG as a negative control. Immu-
noprecipitated samples were subjected to PCR us-
ing primers to amplify the SRE-element in the granu-
philin promoter and for the nonspecific-element (NS).
Mw, molecular weight.
The luciferase activity was normalized to Renilla lu-
ciferase activity, and assays were performed in trip-
licate (B–D and F). Results are expressed as mean6
SEM.indicate that SREBP-1c-mediated inhibition of insulin secretion
can be accounted for, in part, by upregulation of granuphilin.
Activation of SREBP-1c/granuphilin inhibits KSIS in islets
from diabetic mice
The inhibitory effect of theSREBP-1c/granuphilin pathway on in-
sulin secretion was tested in islets frommurine models of diabe-
tes (Figure 5A). Alongwith consistent upregulation of SREBP-1c,
both granuphilin mRNA and protein levels were increased in
islets from genetically obese diabetic mice such as ob/ob,
KK-Ay, and db/db, as compared to control C57BL/6mice. In ad-
dition, mice made obese with high-fat or high-fat/high-sucrose
diets also displayed increased SREBP-1c and granuphilin ex-
pression. We next sought to determine the effect of granuphilin146knockdown on gene expression in islets from KK-Ay mice (Fig-
ures 5B–5E). Comparison of LacZi-Ad-infected islets from
C57BL/6 andKK-Aymice also allowed us to determine basal dif-
ference in gene expression under control and diabetic condi-
tions. mRNA levels of SREBP-1c and granuphilin were elevated
in the KK-Ay mice compared to C57BL/6 controls. Granuphilin
knockdown resulted in essential abolishment of both granuphilin
mRNA and protein levels without impacting SREBP-1c levels
(Figure 5B). Islets from KK-Ay mice had higher basal nuclear
SREBP-1 protein with concomitant increases in SREBP-1c tar-
get genes FAS and UCP-2 with significant increases in triglycer-
ide content (Figures 5E and S4B). Protein levels of Syntaxin-1a
and Munc18-1 were slightly decreased; however, levels of other
vesicle proteins remained unchanged by either the increase inCELL METABOLISM : AUGUST 2006
SREBP-1c/granuphilin pathway in insulin secretionFigure 3. Mouse granuphilin promoter analysis as
a MafA target
A) Schematic representation of the granuphilin pro-
moter with sequence and location of a potential
MafA binding site (MARE).
B) Transcriptional activities of wild-type MafA and
mutant MafA (deletion of transactivation domain,
amino acid 229–359) on Granu-1200-Luc in Min6
cells.
C) Deletion studies in MafA activation of granuphilin
promoter.
D) Effect of mutation in the MARE onMafA activation
of granuphilin. Native (Granu-500-Luc) or mutant-
MARE (mMARE-Luc) reporter gene plasmids were
cotransfected into Min6 cells with pSV40-Renilla
and MafA.
E) EMSA with radio-labeled probes for rat insulin II
MARE and granuphilin MARE-elements. In vitro
translated MafA protein was incubated with these la-
beled probes. Specific binding was confirmed by an
excess of nonlabeled probe.
F) In vivo binding to Granuphilin-MARE. Chromatin
prepared from the Min6 cells were subjected to the
ChIP assay with anti-rabbit MafA antibody and rabbit
IgG as a negative control. Immunoprecipitated sam-
ples were subjected to PCR using primers to amplify
the granuphilin promoter containing the MARE-
element and of a nonspecific-element (NS). Mw,
molecular weight.
G) Dose-dependent effects of MafA with cotransfec-
tion of SREBP-1c on Granu-Luc-1200 in Min6 cells.
H) Dose-dependent effects of SREBP-1c with co-
transfection of MafA on Granu-Luc-1200 in Min6
cells.
The luciferase activity was normalized to Renilla lu-
ciferase activity and performed in triplicate (B–D, G,
and H). Results are expressed as mean 6 SEM.SREBP-1c in the diabetic KK-Aymice or by knockdown of gran-
uphilin (data not shown). Thus, knockdown of granuphilin does
not appear to alter mRNA or protein levels of any other proteins
involved in insulin-containing granule transport in islets. Both
GSIS and KSIS were reduced in KK-Ay islets with a reduction
in theATP/ADP ratio and an increase in thecontent of triglycerides
(Figures 5C–5E). Knockdown of granuphilin completely restored
KSIS but not GSISwithout modulating ATP/ADP ratio or triglycer-
ide content. In addition, restoration of decreased KSIS by granu-
philin knockdown was also observed in islets from ob/ob and
diet-induced obese (DIO) mice (Figures 5F, 5G, S4C, and S4D).
Knockdown of SREBP-1c by adenoviral RNAi was performed
in islets from KK-Ay and ob/ob mice that exhibit upregulation ofCELL METABOLISM : AUGUST 2006SREBP-1c and granuphilin (Figure S5). Although acute inhibition
of SREBP-1c was not complete in these islets, reduction of
granuphilin and restoration of decreased GSIS and KSIS were
partially but consistently observed to support the concept of
the contribution of the SREBP-1c/granuphilin pathway to im-
paired insulin secretion. Combined, these data implicate the
specific involvement of granuphilin in impaired insulin secretion
in obesity-related diabetic mice.
Palmitate lipotoxicity involves inhibition of KSIS
through granuphilin
Saturated fatty acids are known to impair insulin secretion, sup-
porting the theory that lipotoxicity plays a role in impaired b–cell147
A R T I C L EFigure 4. Effects of knockdown of granuphilin on
insulin secretion in pancreatic islets from b cell-
specific nuclear SREBP-1c transgenic mice
Islets were isolated from male age-matched (13- to
18-week-old) Wild-type-Control or TgRIP-SREBP-
1c mice and were infected adenoviral-LacZ-RNAi
or -granuphilin (Granu)-RNAi (500 MOI) for 48 hr.
A) mRNA levels of the human SREBP-1c transgene
and endogenous granuphilin from the indicated islets
as estimated by real-time PCR. hSREBP-1c levels
were calculated as copy numbers.
B) Immunoblot analysis of SREBP-1, MafA, and
granuphilin from the indicated islets.
C) Immunoblot analysis of the fusion machinery for
exocytosis of insulin granules from the indicated is-
lets with a-tubulin as a loading control.
D) Cellular ATP/ADP ratio from the indicated islets.
E) Cellular TG content from the indicated islets.
F) LG-, HG-, and KCl-stimulated insulin secretion in
the indicated islets: WT-LacZ-RNAi (white bars),
WT-Granuphilin-RNAi (black bars), TgRIP-SREBP-
1c-LacZ-RNAi (light gray bars), and TgRIP-SREBP-
1c-Granuphilin-RNAi (dark gray bars).
Results were normalized to cellular DNA content (F)
and are expressed as mean 6 SEM. *p< 0.01 and
**p < 0.05 (versus WT-LacZi). Studies were per-
formed in triplicate with sets of islets pooled from
3–4 mice per replicate.function (Dubois et al., 2004; Joseph et al., 2004). To test
whether granuphilin expression might contribute to the patho-
physiologic consequences of lipotoxicity, we incubated isolated
islets with palmitate (PA) for 48 hr. PA induced both SREBP-1c
and granuphilin in normal islets at both mRNA and protein levels
(Figures 6A, 6B, and S4E). These inductions were blunted in
the absence of SREBP-1c, indicating that SREBP-1c plays
a dominant role in PA-induced granuphilin expression. PA
reduced KSIS as well as GSIS in SREBP-1c-normal mice;
however, the PA-suppressed GSIS and KSIS were almost
completely restored in SREBP-1-null mice (Figure 6C). These
results suggested that PA-induced insulin secretion impairment
is mediated through SREBP-1c. Furthermore, we used adenovi-
ral-granuphilin RNAi treatment to completely suppress granu-
philin expression in control and PA-treated islets (Figures 6D148and S4F). The absence of granuphilin significantly ameliorated
the suppression of both GSIS and KSIS induced by PA
(Figure 6E), indicating that granuphilin upregulation is involved
in PA-induced impairment of insulin secretion. PA induction of
SREBP-1c/granuphilin was investigated at the transcriptional
level in MIN6 cells. Both Granu-1200-Luc (Figure 6F) and SRE-
Luc (data not shown) were activated by incubation with PA, in-
dicating that induction of nuclear forms of endogenous SREBPs
and granuphilin was at the transcriptional level. Knockdown of
SREBP-1c led to a strong reduction in PA induction of the gran-
uphilin promoter, but dominant-negative mutant MafA did not.
These data demonstrated that incubation of isolated islets
with PA, a model for lipotoxicity in b cells, caused impaired insu-
lin secretion at least partially through induction of SREBP-1c
and granuphilin.CELL METABOLISM : AUGUST 2006
SREBP-1c/granuphilin pathway in insulin secretionFigure 5. Activation of SREBP-1c and granuphilin in
pancreatic islets from different diabetic model mice
and effects of granuphilin knockdown on insulin
secretion
Islets were isolated from male C57BL/6, ob/ob, KK,
KK-Ay (10 weeks old), db/misty, and db/db mice
(6 weeks old). C57BL/6, KK-Ay, and ob/ob mice is-
lets were infected adenoviral-LacZ-RNAi or -granu-
philin(Granu)-RNAi (500 MOI) for 48 hr.
A) Upper panel: immunoblot analysis of granuphilin
from the indicated mice with a-tubulin as a loading
control. Lower panel: mRNA levels of SREBP-1c
(white bars) and granuphilin (black bars) in the islets
from the indicated mice as estimated by real-time
PCR. HF: high-fat diet, HF/HS: high-fat and high-su-
crose diet. *p < 0.01 (versus C57BL/6).
B) Upper panel: immunoblot analysis of granuphilin
and SREBP-1 from the indicated islets. Lower panel:
mRNA levels of SREBP-1c (white bars) and granu-
philin (black bars), from the indicated islets.
C) LG-, HG-, and KCl-stimulated insulin secretion in
the indicated islets: C57BL/6-LacZ-RNAi (white
bars), KK-Ay-LacZ-RNAi (black bars), and KK-Ay-
Granuphilin-RNAi (gray bars).
D) Cellular ATP/ADP ratio from the indicated islets.
E) Cellular TG content from the indicated islets.
F) Upper panel: immunoblot analysis of granuphilin
and SREBP-1 from the indicated islets. Lower panel:
LG-, HG-, and KCl-stimulated insulin secretion in the
indicated islets: C57BL/6-LacZ-RNAi (white bars),
ob/ob-LacZ-RNAi (black bars), and ob/ob-Granuphi-
lin-RNAi (gray bars).
G) Upper panel: immunoblot analysis of granuphilin
and SREBP-1 from indicated islets. Lower panel:
LG-, HG-, and KCl-stimulated insulin secretion in
the indicated islets: LacZ-RNAi (white bars), Granu-
philin-RNAi (black bars).
Results were normalized to cellular DNA content (C,
F, and G) and are expressed as mean 6 SEM. *p <
0.01 and **p < 0.05 (versus C57BL/6-LacZ, B-E).
Studieswere performed in triplicatewith sets of islets
pooled from 3–4 mice per replicate.SREBP-1c inhibition of KSIS is abolished
in granuphilin KO islets
Finally, the SREBP-1c effect on insulin secretion was investi-
gated in islets from granuphilin-null mice (Figure 7). Adenoviral
nuclear SREBP-1c caused changes in its target genes, ATP/
ADP ratio, and triglyceride content in both wild-type and granu-
philin KO islets in a similar manner to those in SREBP-1c trans-
genic islets (Figures 7A–7E). As compared to wild-type islets,
both GSIS and KSIS were increased in the absence of granuphi-
lin. Suppression of KSIS bySREBP-1c overexpression observed
in granuphilin-normal islets was cancelled in granuphilin KO
islets. Meanwhile, SREBP-1c-mediated inhibition of GSIS was
partially ameliorated, but remained significantly reduced com-
pared to controls (Figure 7F). Taken together with the dataCELL METABOLISM : AUGUST 2006from granuphilin knockdown in SREBP-1c transgenic islets,
these data demonstrate that granuphilin contributes to
SREBP-1c-mediated KSIS inhibition.
Discussion
Granuphilin is a target gene of SREBP and MafA
Our current study clearly shows that mouse granuphilin is an
SREBP target. Because SREBP-1c expression is highly regu-
lated by nutrition (Horton et al., 1998; Hasty et al., 2000; Matsu-
zaka et al., 2004) and is upregulated in pathological states re-
lated to over-nutrition and insulin resistance (Biddinger et al.,
2005), we propose that SREBP-1-induced granuphilin activation
may contribute to b cell lipotoxicity and diabetes that can149
A R T I C L EFigure 6. Involvement of granuphilin in insulin secre-
tion from isolated murine islets treated with palmitate
Islets were isolated from male age-matched (13- to
17-week-old) SREBP-1-null, SREBP-1(2/2), and
wild-type littermate, SREBP-1 (+/+), mice. The islets
were incubated with 400 mMpalmitate (PA) (A–E) and
were infected with adenoviral-LacZ-RNAi or -granu-
philin-RNAi (500 MOI) for 48 hr (D and E).
A) mRNA levels of SREBP-1c (white bars) and gran-
uphilin (black bars) from the indicated islets as
estimated by real-time RT-PCR. * p < 0.01 (versus
SREBP-1(+/+)-Control). ND, not detectable.
B) Immunoblot analysis of SREBP-1, MafA, and
mouse granuphilin from indicated islets with a-tubu-
lin as a loading control.
C) LG-, HG-, and KCl-stimulated insulin secretion in
SREBP-1(+/+)-control group (white bars), -PA group
(black bars), SREBP-1(2/2)-control group (light gray
bars), and -PA group (dark gray bars). *p < 0.01 and
**p < 0.05 (versus SREBP-1(+/+)-Control).
D)Upper panel: immunoblot analysis of mouse gran-
uphilin and SREBP-1. Lower panel: expression of
SREBP-1c (white bars) and granuphilin (black bars)
from the indicated islets as estimated by real-time
RT-PCR. *p < 0.01 (versus Control-LacZ-RNAi).
E) LG-, HG-, and KCl-stimulated insulin secretion in
islets untreated (Control) or treated with palmitate
(PA), and infected with Adeno-LacZ-RNAi (LacZi-
Ad) or Adeno-granuphilin RNAi (granuphilin RNAi-
Ad). *p < 0.01 (versus Control-LacZi).
F) Effects of SREBP-1-RNAi and mutant MafA on
Granu-1200-Luc in PA treated Min6 cells. The lucif-
erase activity was normalized to Renilla luciferase
activity and performed in triplicate.
Results were normalized to cellular DNA content (C
and E) and are expressed by mean 6 SEM. Studies
were performed in triplicate with sets of islets pooled
from three to four mice per replicate.develop in these situations. We also show that the granuphilin
promoter is activated by MafA. MafA has recently been estab-
lished to be crucial for normal structure and function of b cells
and insulin gene expression (Hagman et al., 2005; Kajihara
et al., 2003) and thus is likely to be responsible for b cell-specific
basal expression of granuphilin. Supportively, basal expression
of granuphilin was severely diminished in islets from MafA
knockout mice (S.T., unpublished data), while it was only 50%
reduced in homozygous SREBP-1-null islets.
Granuphilin activation inhibits insulin secretion
Granuphilin has been thought to be a component of the fusion
machinery for exocytosis of insulin granules. However, activa-
tion of granuphilin leads to inhibition of insulin secretion. Al-150though the exact molecular mechanisms involved are yet un-
known, various gain- and loss-of-function experiments from
our current data as well as published reports strongly suggest
that this Rab27a effector is a potent inhibitor of insulin secretion
(Coppola et al., 2002; Gomi et al., 2005; Torii et al., 2002).
SREBP-1c and thus granuphilin was activated in islets from
SREBP-1c transgenic, KK-Ay, ob/ob, and DIO mice, as well as
in islets treated with PA. Decreased KSIS in these islets were
all restored by granuphilin knockdown, demonstrating that gran-
uphilin plays a crucial role in the disturbance of insulin secretion
post-ATP production. In combination with granuphilin activa-
tion, syntaxin-1a and Munc18-1, components of this docking
machinery, were decreased by SREBP-1c activation and thus,
may also be involved in the secretion impairment. DysregulationCELL METABOLISM : AUGUST 2006
SREBP-1c/granuphilin pathway in insulin secretionFigure 7. Effect of overexpression of nuclear
SREBP-1c on insulin secretion in pancreatic islets
from granuphilin-null mice
Islets were isolated from male age-matched (30- to
32-week-old) granuphilin-null (Granu(2/Y)) and
wild-type littermate (Granu(+/Y)) mice. The islets
were infected with adenoviral-GFP or -SREBP-1c
(500 MOI) for 48 hr.
A) Immunoblot analysis of SREBP-1, granuphilin,
and Rab27a from the indicated islets with a-tubulin
as a loading control.
B)mRNA levels of indicated genes from the indicated
islets as estimated by real-time RT-PCR.Granu(+/Y)-
GFP (white bars), Granu(+/Y)-SREBP-1c (black
bars), Granu(2/Y)-GFP (light gray bars), and
Granu(2/Y)-SREBP-1c (dark gray bars).
C) mRNA levels of human SREBP-1c (hBP-1c) and
granuphilin (Granu) from the indicated islets as
estimated by real-time RT-PCR. Lane 1, Granu(+/
Y)-GFP; lane 2, Granu(+/Y)-SREBP-1c; lane 3,
Granu(2/Y)-GFP; lane 4, Granu(2/Y)-SREBP-1c.
D) Cellular ATP/ADP ratio from the indicated islets.
E) Cellular TG content from the indicated islets.
F) Upper panel: HG and KCl-stimulated insulin se-
cretion ratio, normalized by LG-stimulated insulin se-
cretion. Lower panel: HG- and KCl-stimulated insulin
secretion in Granu(+/Y)-GFP (white bars), Granu(+/
Y)-SREBP-1c (black bars), Granu(2/Y)-GFP (light
gray bars), and Granu(2/Y)-SREBP-1c (dark gray
bars).
Results were normalized to cellular DNA content (F)
and are expressed bymean6 SEM. *p <0.01 (versus
Granu(+/Y)-GFP) and #p < 0.01 (versus Granu(2/Y)-
GFP). Studies were performed in triplicate with sets
of islets from 3–4 mice per replicate.of these three proteinsmay impair insulin secretion by disturbing
the balance of vesicle transport component concentrations.
Potential involvement of SREBP-1c/granuphilin pathway
in b cell lipotoxicity
Weshowed that upregulation of granuphilin is observed in b cells
not only from transgenic mice overexpressing SREBP-1c but
also from obesity-associated insulin resistant diabetic mice
such as KK-Ay, ob/ob, and DIO mice, leading to a reduction of
KSIS. It has been believed that impaired GSIS, due to deteriora-
tion of glucose metabolism characterized by decreased ATP/
ADP ratio and/or insulin production in b-cells, is responsible
for the insulin secretion defect in type 2 diabetes (Weir and Bon-
ner-Weir, 2004). Our current data demonstrate that additional
disturbances can also occur at the exocytosis stage of insulinCELL METABOLISM : AUGUST 2006secretion in diabetic models. Impaired KSIS was primarily
mediated through activation of granuphilin, providing another
mechanism for development of diabetes. Overexpression of
granuphilin also inhibited GSIS in normal islets, but this was be-
cause the path to GSIS also includes the process of KSIS, and
disturbance causing decreased KSIS should result in impaired
GSIS as well. Supportively, granuphilin knockdown efficiently
restored impaired KSIS in SREBP-1c transgenic and diabetic
islets but only partially restored GSIS, indicating that the
SREBP-1c/granuphilin effect was specific to the process post-
ATP production.
Our data also provide further evidence that SREBP-1c is inti-
mately involved in b cell dysfunction. In islets from the mice with
lipotoxicity and diabetes, SREBP-1c is upregulated and contrib-
utes to disturbances in ATP production leading to impairedGSIS151
A R T I C L Eand also to upregulation of granuphilin leading to attenuated
KSIS. Various approaches using gene engineering and adenovi-
rus consistently supported this hypothesis. Thus, the SREBP-
1c/granuphilin pathway should be added to the list of potential
mechanisms for b cell lipotoxicity in diabetes and could be a po-
tential target for therapy of obesity-related diabetes. In contrast,
it was reported that granuphilin as well as Rab27a and 3 were
suppressed in a glucotoxic state of INS-1 cells through induc-
tion of ICER (Abderrahmani et al., 2006). Further studies are
needed to elucidate the precise molecular role of granuphilin
in insulin secretion and to determine the extent to which granu-
philin contributes to diabetes in humans.
Experimental procedures
Materials
All chemical compounds were obtained from Sigma chemicals. Enhanced
chemiluminescence Western blot detection kit and redivue [a-32P] dCTP
were purchased from Amersham Pharmacia and restriction enzymes were
from Takara Bio Inc.
Animals
All animal studies were approved by the Animal Care Committee of University
of Tsukuba. Male C57BL/6, ob/ob, db/m, and db/db mice were purchased
from Charles River Laboratories. KK and KK-Ay were purchased from
Clea. RIP-human nuclear SREBP-1c transgenic mice (Takahashi et al.,
2005), SREBP-1-null mice (Shimano et al., 1997b), and Granuphilin-null
mice (Gomi et al., 2005) were generated as previously described. Animals
were adapted to environments for 1 week before isolation of pancreatic
islets. The mice were housed in colony cages and maintained on a 12 hr
light/12 hr dark cycle and given free access to water and a standard chow
diet (MF, Oriental yeast).
Expression plasmids
All expression vectors were produced as previously described (Amemiya-
Kudo et al., 2000, 2005; Ide et al., 2004; Kajihara et al., 2003; Yamamoto
et al., 2004).
Reporter plasmid
The reporter plasmid Granu-1200-Luc contains a fragment of the granuphilin
promoter from 21200 to +87 bp cloned into the MluI/XhoI sites of the pGL3
basic vector (Promega) containing the coding sequences of firefly luciferase
cDNA. Other constructs were produced by PCR using this construct as a
DNA template, and the PCR products were inserted into pGL3 basic vector.
The primers used for PCR were as follows: 50 primers Granu-1200-Luc
50-taagcgttgagaaatgaatg-30, Granu-500-Luc 50-agggttgcttacagggcgat-30,
Granu-300-Luc 50-tcgctgaacaaaaaggcaag-30, Granu-265-Luc 50-ttcctacccc
cacccccgac-30, Granu-174-Luc 50-tgctaactcaggaggaaattc-30, Granu-150-
Luc 50-aattcctccagtgccttaag-30, and 30 primer 50-ggtccgggtgccgaatg-30. Re-
striction sites MluI and XhoI were added to each 50 primer and 30 primer,
respectively. The site-directedmutagenesis constructsmSRE- andmMARE-
Luc were produced by PCR with the following primers: mSRE-50 50-attcccat
tccgtaccccacccccgacccc-30, -30 50-ggggtcgggggtggggtacggaatgggaat-30,
mMARE-50 50-tcaaactctcagaactcaggaggaaattcc-30, and -30 50-ggaatttcctcc
tgagttctgagagtttga-30. SRE-Luc was produced as previously described
(Amemiya-Kudo et al., 2000).
Cell cultures, transfection, and luciferase assays
Min6 cells were cultured at 37C in atmosphere of 5% CO2 in Dulbecco’s
modified Eagle’s Medium (DMEM) with 25 mM glucose supplemented with
15% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin, and
b-mercaptoethanol. Each expression plasmid (0–0.5mg), luciferase reporter
plasmid (0.2 mg), and pSV40-Renilla plasmid (0.05 mg) were cotransfected
using the LipofectAMINE reagent (Invitrogen) according to manufacture’s
instructions. Min6 cells were seeded in 24-well plates at a density of 3 3
105 cells/well. The total amount of DNA was adjusted to 0.5–1 mg/well with
empty vector DNA. After 48 hr of transfection, cells were washed with phos-
phate-buffer saline (PBS) and harvested. Luciferase assays were carried out152according to the manufacture’s instructions (Promega), and luciferase activ-
ity was quantified by using ALOVA 1420 multilabel counter (Perkin Elmer Life
Sciences). As the internal standard, SV40 Renilla luciferase control vector
was also cotransfected to normalize for transfection efficiency.
Gel mobility shift assay
Gel mobility shift assays (EMSA) were performed as previously described
(Amemiya-Kudo et al., 2005; Nakagawa et al., 2006; Yamamoto et al.,
2004). In brief, recombinant SREBPs (SREBP-1a, -1c,and -2) and MafA pro-
teins were produced using the TNT T7 quick-coupled transcription/transla-
tion system (Promega). The reaction mixture were incubated with in vitro
synthetic protein lysate and then analyzed on 4% polyacrylamide gels.
Super-shift reactions were performed by adding antibody (anti-SREBP-1,
sc-8984 Santa Cruz) to the reaction mixture. The DNA probes for EMSA
are followed: granuphilin-SRE, aactttattcccattcctacccccacccccgaccccaatc
atctaagaga, granuphilin-mSRE, aactttattcccattccgtaccccacccccgaccccaat
catctaagaga, granuphilin-MARE, cctcaaactctgctaactcaggaggaaattcctccagtg
cc, and granuphilin-mMARE, cctcaaactccagtaactcaggaggaaattcctccagtgcc.
Isolation of mouse pancreatic islets and insulin
secretion experiments
Isolation of islets from mice was carried out using the Ficol-Conray protocol
as previously described(Scharp et al., 1973; Takahashi et al., 2005). Briefly,
4 mg/ml collagenase was injected into the pancreatic duct and incubated
at 37C for 20 min. The islets were subsequently purified by Ficol gradient
and hand picking. The remaining islets were cultured for 2 hr at 37C in a hu-
midified atmosphere containing 5% CO2 and in regular RPMI-1640 medium
supplemented with 10% FCS (pH 7.4) prior to the experiments. Insulin re-
lease from islets was measured as previously described (Takahashi et al.,
2005). In brief, groups of 10 islets of similar size for each condition were pre-
incubated in Krebs-Ringer bicarbonate buffer (KRBH [pH 7.4]) containing
0.5% BSA at 2.8mM glucose for 30 min. Islets were then incubated with
1 ml of KRBH with 0.5% BSA at 2.8mM glucose (low glucose; LG), 20mM
glucose (high glucose; HG), 30mM KCl with 2.8 mM glucose (KCl), 3mM
Arginine with 2.8 mM glucose, forscolin (10mM) with 2.8 mM glucose, or
TPA (0.5 mM) with 2.8 mM glucose, respectively. Subsequently, medium
were replaced with fresh medium for insulin determination followed by total
islet insulin extraction by 0.5ml of cold acid ethanol mixture (75% ethanol
with 0.2M HCl). Hoechst-33258 staining of sonicated islets was performed
to determine the islet DNA content.
Determination of ATP/ADP ratio and triglyceride contents of islets
ATP and ADP content in isolated islets were determined as previously de-
scribed (Schultz et al., 1993; Takahashi et al., 2005). In brief, after preincuba-
tion at 37C for 30 min in KRBH buffer containing 2.8 mM glucose, groups of
25 islets were incubated at 37C for 30 min in KRBH buffer containing 20mM
glucose. The conversion from ADP to ATP was performed in the reaction
buffer (20mM HEPES and 3mM MgCl2 [pH 7.75]) containing 2.3 U/ml pyru-
vate kinase and 1.5mM phosphoenolpyruvate at room temperature for
15 min. ATP and ADP were extracted from islets with 100 ml of 5% trichloro-
acetic acid (TCA). After centrifugation, the supernatants were neutralized
with NaOH. ATP content was measured using CellTiter-Glo luminescent
cell viability assay kit (Promega).
Real-time PCR and immnoblot analysis
Comparative analysis of mRNA levels was performed with fluorescence-
based real-time PCR. Total RNA extraction and first-strand cDNA synthesis
were previously as described (Takahashi et al., 2005). Quantitative real-time
PCR was performed using Sybr-Green Dye (Nihon Gene) in an ABI 7000
PCR instrument (AppliedBiosystems).Relative abundance for each transcript
was calculated by a standard curve of cycle thresholds for serial dilutions of a
cDNA sample and normalized to cyclophilin. Primer sequences are available
upon request. For immnoblot blots, total or nuclear cell extracts of isolated
islets (Hagman et al., 2005; Takahashi et al., 2005) and nuclear extracts
from Min6 cells (Amemiya-Kudo et al., 2005) were prepared as described
previously, separatedbySDS-PAGE, transferred to immobilon-Pmembranes
(Millipore), and were probed with polyclonal anti-SREBP-1 (sc-8984), anti-
Rab27a (sc-22756), anti-a-tubulin (sc-5282, Santa Cruz), anti-MafA (A-300-
611, Bethyl Lab. Inc.), anti-syntaxin-1a (S1172, Sigma), anti-Vamp2
(627724, Calbiochem), anti-Rab3 (R35520), anti-Munc18-1 (M32320), andCELL METABOLISM : AUGUST 2006
SREBP-1c/granuphilin pathway in insulin secretionanti-SNAP25 (S35020, BD) antibodies. Detection was performed using an
ECL advance Western blotting ECL detection kit and Hyperfilm (Amersham
Biosciences). Anti-granuphilin-a/b antibody was as previously described
(Gomi et al., 2005).
Northern blot analysis
Northern blot analysis was performed as previously described (Amemiya-
Kudo et al., 2005; Matsuzaka et al., 2004). cDNA probe for granuphilin was
prepared from reverse transcriptase for PCR of Min6 cells total RNA with
the following primers: 50-cgagatggaaagggatttga-30 for sense and 50-gtctgc
tgaaggagggactg-30 for antisense of granuphilin.
Preparation of recombinant adenovirus
The construct of granuphilin-a coding cDNA was generated by PCR amplifi-
cation and into the pShuttle-CMV vector (Ide et al., 2004; Nakagawa et al.,
2006). The following primers were used: 50 primer, 50-atgtcggagatactagacc
tctctt-30, and 30 primer 50-catacacccagcttctgcttgaccat-30. Generation of re-
combinant adenoviral plasmid was produced by homologous recombination
with the pAdEasy-1 plasmid. The siRNA construct for mouse granuphilin and
SREBP-1 was generated in the coding sequence; Granuphilin-RNAi-784
50-gagcgagagtctggatagctaca-30, Granuphilin-RNAi-1955 50-aggctggaagatct
acaacaaat-30, and SREBP-1-RNAi 50-ggcaaaggaggcactacag-30. Oligonucle-
otide containing this sequence was subcloned into U6/RNAi empty vector
(Invitrogen). Granuphilin RNAi adenoviruses were generated using BLOCK-
iT Adenoviral RNAi Expression System (Invitrogen). Production of recombi-
nant adenoviruses was performed by CsCl gradient centrifugation as
previously described (Ide et al., 2004).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were performed as previously
described (Amemiya-Kudo et al., 2005; Nakagawa et al., 2006). To amplify
the granuphilin promoter region containing SRE and MARE, the following
primer sets were used: for SRE 50-gtactttactattggacaac-30 for sense, 50-
ccttaaggcactggaggaatttc-30 for antisense, and for MARE 50-gtgagcaaagata
gactaga-30 for sense, 50-tggagcggggaggagctggactc-30 for antisense. The
PCR conditions were 5 min at 95C and 30 cycles of 30 s at 94C, 30 s at
57C and 1 min 72C for SRE region, and 10 min at 94C and 30 cycles of
10 s at 98C, 30 s at 54C, and 1 min 72C for MARE region.
Palmitate treatment
Palmitate was dissolved in ethanol as 100 mM stock solution with 0.5% fatty
acid free BSA (Sigma). For using experiments, palmitate was diluted in
DMEM supplemented with 0.5% fatty acid free BSA to a final concentration
of 400 mM for islets study or 200 mM for Luc-assay.
Statistical analysis
Values are expressed as mean6 standard error of the mean (SEM). Statisti-
cal comparisons were performed using analysis of variance (ANOVA).
Supplemental data
Supplemental data include five figures and can be found with this article
online at http://www.cellmetabolism.org/cgi/content/full/4/2/143/DC1/.
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